We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
Read MoreHide Full Article
Ligand Pharmaceuticals Incorporated (LGND - Free Report) reported third-quarter 2019 adjusted earnings of 49 cents per share, which missed the Zacks Consensus Estimate of 65 cents. The company had reported adjusted earnings of $1.32 in the year-ago quarter. Third-quarter adjusted earnings exclude the impact of non-cash charge of $10.5 million related to Ligand’s investment in Viking Therapeutics, stock-based compensation and non-cash charges.
Total revenues decreased to $24.8 million from $45.7 million in the year-ago quarter due to lower royalty revenues. However, the top line surpassed the Zacks Consensus Estimate of $23.16 million.
Shares of Ligand have declined 17.6% so far this year against the industry’s 0.7% increase.
Quarterly Highlights
Royalty revenues were $9.8 million in the third quarter compared with $36.1 million in the year-ago quarter. Ligand primarily earns royalties on sales of Amgen's (AMGN - Free Report) Kyprolis and CASI Pharmaceuticals' (CASI - Free Report) Evomela, which were developed using its Captisol technology. The significant decline in royalty revenues was due to loss of royalties from sales of Novartis’ (NVS - Free Report) blockbuster drug, Promacta. In March, Ligand sold Promacta rights, including royalty rights to worldwide net sales, to privately-held Royalty Pharma for $827 million.
Please note that, excluding Promacta royalties recorded in the year-ago quarter, royalty revenues increased almost 39% year over year in the third quarter. The growth was driven by higher royalties on Kyprolis as the drug’s sales reachedhigher royalty rate tier and higher sales of Evomela following its launch in China. CASI Pharmaceuticals launched Evomela in China in August.
License fees, milestones and other revenues were $8.2 million in the third quarter compared with $2.5 million a year ago. Material sales were $6.8 million, down 2.9%.
Adjusted general and administrative expense was $5.6 million in the third quarter, down 11.1% from the year-ago quarter. Adjusted research and development expense doubled year over year to $6.2 million.
Business Developments
In July 2019, Ligand acquired privately-held Ab Initio and added antigen discovery platform to its portfolio. The company also inked new OmniAb license agreements with six companies, including Japanese pharma company, Takeda Pharmaceutical. It entered into agreements related to its Captisol technology with several companies during the quarter.
In September, Amgen announced successful completion of a phase III study evaluating Kyprolis in combination with dexamethasone and J&J’s cancer drug, Darzalex. The company also signed an agreement to commercialize Kyprolis in China. In July, Ligand’s partner Sage Therapeutics announced the launch of its postpartum depression drug, Zulresso.
2019 Guidance
Ligand reiterated its sales guidance for 2019 of approximately $118 million. However, it lowered adjusted earnings view from $3.20 per share to $3.00 for 2019, which reflects certain changes in tax expense, especially related to sale of Promacta royalty right. The Zacks Consensus Estimate for revenues and earnings are pegged at $118.59 million and $3.25 per share, respectively.
Ligand Pharmaceuticals Incorporated Price, Consensus and EPS Surprise
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
Ligand Pharmaceuticals Incorporated (LGND - Free Report) reported third-quarter 2019 adjusted earnings of 49 cents per share, which missed the Zacks Consensus Estimate of 65 cents. The company had reported adjusted earnings of $1.32 in the year-ago quarter. Third-quarter adjusted earnings exclude the impact of non-cash charge of $10.5 million related to Ligand’s investment in Viking Therapeutics, stock-based compensation and non-cash charges.
Total revenues decreased to $24.8 million from $45.7 million in the year-ago quarter due to lower royalty revenues. However, the top line surpassed the Zacks Consensus Estimate of $23.16 million.
Shares of Ligand have declined 17.6% so far this year against the industry’s 0.7% increase.
Quarterly Highlights
Royalty revenues were $9.8 million in the third quarter compared with $36.1 million in the year-ago quarter. Ligand primarily earns royalties on sales of Amgen's (AMGN - Free Report) Kyprolis and CASI Pharmaceuticals' (CASI - Free Report) Evomela, which were developed using its Captisol technology. The significant decline in royalty revenues was due to loss of royalties from sales of Novartis’ (NVS - Free Report) blockbuster drug, Promacta. In March, Ligand sold Promacta rights, including royalty rights to worldwide net sales, to privately-held Royalty Pharma for $827 million.
Please note that, excluding Promacta royalties recorded in the year-ago quarter, royalty revenues increased almost 39% year over year in the third quarter. The growth was driven by higher royalties on Kyprolis as the drug’s sales reachedhigher royalty rate tier and higher sales of Evomela following its launch in China. CASI Pharmaceuticals launched Evomela in China in August.
License fees, milestones and other revenues were $8.2 million in the third quarter compared with $2.5 million a year ago. Material sales were $6.8 million, down 2.9%.
Adjusted general and administrative expense was $5.6 million in the third quarter, down 11.1% from the year-ago quarter. Adjusted research and development expense doubled year over year to $6.2 million.
Business Developments
In July 2019, Ligand acquired privately-held Ab Initio and added antigen discovery platform to its portfolio. The company also inked new OmniAb license agreements with six companies, including Japanese pharma company, Takeda Pharmaceutical. It entered into agreements related to its Captisol technology with several companies during the quarter.
In September, Amgen announced successful completion of a phase III study evaluating Kyprolis in combination with dexamethasone and J&J’s cancer drug, Darzalex. The company also signed an agreement to commercialize Kyprolis in China. In July, Ligand’s partner Sage Therapeutics announced the launch of its postpartum depression drug, Zulresso.
2019 Guidance
Ligand reiterated its sales guidance for 2019 of approximately $118 million. However, it lowered adjusted earnings view from $3.20 per share to $3.00 for 2019, which reflects certain changes in tax expense, especially related to sale of Promacta royalty right. The Zacks Consensus Estimate for revenues and earnings are pegged at $118.59 million and $3.25 per share, respectively.
Ligand Pharmaceuticals Incorporated Price, Consensus and EPS Surprise
Ligand Pharmaceuticals Incorporated price-consensus-eps-surprise-chart | Ligand Pharmaceuticals Incorporated Quote
Zacks Rank
Ligand currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>